Last reviewed · How we verify
HG146
At a glance
| Generic name | HG146 |
|---|---|
| Also known as | HG146 Capsule, HG280146, HG0146, HG280146, HG280146-P1 |
| Sponsor | HitGen Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma (PHASE2)
- Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma (PHASE1)
- A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HG146 CI brief — competitive landscape report
- HG146 updates RSS · CI watch RSS
- HitGen Inc. portfolio CI